ArticleContemporary clinical trials communications2020

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.

Alkomiet Hasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.